NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Dr. Liau's trial is funded by NCI that is a division of NIH -- not anything to do with FDA. Dr. Liau is also using PFS as the lead efficacy endpoint for the Combo trial. She also confirmed that the PFS primary endpoint for the NWBO trial after 14 years of observations and claimed that she had method to identify pseudo-progression. But yet NWBO tossed out the PFS endpoint when they failed.